$47.130
+1.254 (+2.66%)At close
GPCR News
GPCR Events
Structure Therapeutics Publishes Phase 2b Trial Results for Aleniglipron
Structure Therapeutics announced a publication in Nature Medicine detailing results from the Phase 2b ACCESS clinical trial of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity. The Nature Medicine publication, titled, "Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial," can be accessed online. The publication was released concurrent with an oral presentation during the American Diabetes Association's 86th Scientific Sessions by lead author, Julio Rosenstock, MD, Chair of the aleniglipron program Steering Committee and Clinical Professor of Medicine, University of Texas, Southwestern Medical Center. The data highlights the efficacy from three maintenance dose levels in the core Phase 2b ACCESS study, as well as a predefined interim analysis of the open-label extension safety study that demonstrated the durability of weight loss beyond 36 weeks, and improved tolerability from a lower 2.5 mg starting dose. The data from these studies provide support for the study design of the upcoming Phase 3 program which is expected to initiate in the third quarter of 2026. "The data published today provide important new details around the previously reported reductions in body weight in patients dosed with aleniglipron. Interestingly, participants continued to lose weight after a median follow up of 20 weeks in the open label extension phase of the study after finalizing the 36 weeks in the double-blind treatment period, with no apparent weight loss plateau. This is an important distinction for a once-daily oral, non-peptide GLP-1 receptor agonist to potentially become an additional treatment option for patients," stated Dr. Rosenstock, MD, Chair of the Steering Committee. "The study closely monitored the participant experience and additional impacts across key measures of tolerability, including the ability to restart or increase dosing titration after interruption without substantial increase in emesis events, which may be helpful for clinicians to gain a clinical perspective of treatment tolerance."
Structure Therapeutics Appoints Matthew Lang as COO and General Counsel
Structure Therapeutics announced the appointment of Matthew Lang as COO and general counsel. Lang most recently served as chief legal officer and secretary at Metsera.
Structure Therapeutics Announces Aleniglipron Clinical Data
Structure Therapeutics announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity. This includes 44-week data from the Phase 2 ACCESS II study and interim data from the ongoing body composition study and the ACCESS open label extension study. Aleniglipron is an investigational orally-available, once-daily, nonpeptide small molecule agonist of the glucagon-like-peptide-1 receptor designed to address patient needs and accessibility. In the Phase 2 ACCESS II study, aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks. In the ACCESS OLE study, aleniglipron achieved continued weight loss from 36 weeks, up to 16.2% with 120 mg at 56 weeks. Both studies continue to demonstrate no evidence of weight loss plateau. Aleniglipron continues to demonstrate a tolerability profile that is consistent with the GLP-1 receptor agonist class and a compelling safety profile with no off-target events. In ACCESS II, across all active arms in participants who reached doses 120 mg or higher from 28 to 44 weeks, there was only one adverse event-related treatment discontinuation. With a median follow-up of 20 weeks, the tolerability data as of the February 20, 2026 cutoff date from the interim analyses of the OLE and the body composition studies provide further support that the use of 2.5 mg as a lower starting dose very meaningfully reduces the rate of AE-related discontinuations during the titration phase. In the OLE, with a median follow-up of 20 weeks, there was an overall AE-related discontinuation rate of 2%. In the body composition study, with a median follow-up of 20 weeks, there was an overall AE-related discontinuation rate of 3.4% in the aleniglipron arm. Together, these positive efficacy, tolerability and safety findings continue to support the advancement of aleniglipron into Phase 3 clinical development, with initiation anticipated in the second half of 2026.
Major Averages Broadly Lower as Tech Stocks Decline
The major averages were broadly lower near noon as tech stocks continue to decline and as investors continue to analyze earnings, monetary policy news, and macroeconomic data. On the macro side, markets are digesting the implications of the nomination of Kevin Warsh as the next Federal Reserve Chair. Warsh's nomination has lifted the U.S. dollar and pressured commodities like gold and silver, while traders recalibrate expectations for interest rates and policy continuity. At the same time, the upcoming week's heavy slate of earnings and labor market data looms as a catalyst for direction in equities.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump has nominatedApplereportedand provided Q2 revenue guidanceChevronand Exxon Mobilboth reportedVerizonreportedand authorized a $25B share repurchase programAmerican Expressand Visaboth reported2. WALL STREET CALLS:HSBCPinterestto Hold on softer near-term outlookSanDiskto Outperform at Raymond JamesCodere Onlineto Hold at StifelSpotifyto Buy at CitiSouthwestto Outperform at BMO Capital3. AROUND THE WEB:Alibabaand ByteDance both plan to release flagship AI models around China's mid-February Lunar New Year holiday, including ByteDance's Doubao 2.0, The Information saysAccording to new NHTSA crash data and Tesla'snew disclosure of Robotaxi mileage, Tesla's driverless vehicles are crashing at a much higher rate than human drivers, even with a safety monitor in every vehicle, Electrek reportsGameStopshares have dropped 80% since becoming a meme stock in 2021, but GameStop CEO Ryan Cohen plans to turn the $11B company into a $100B juggernaut, WSJ saysNvidiaassisted China's DeepSeek with refining its AI models that were later used in the Chinese military, Reuters reportsStructure Therapeutics, which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios says4. MOVERS:Robert Halfgains afterand provided guidance for Q1Deckers Outdoorincreases afterand raising its guidance for FY26Critical Metals (CRML) lower in New York afterto fast track the development of its Tanbreez projectLexiconfalls after announcing aPennyMac Financiallower after5. EARNINGS/GUIDANCESoFi Technologiesand provided guidance for Q1 and FY26GCL Globalresults and cut its guidance for FY26Church & Dwight, with CEO Rick Dierker commenting, "we are pleased to deliver another year of industry-leading results"Colgate-Palmolive, with EPS and revenue beating consensusAon plc, with CEO Greg Case commenting, "Our fourth-quarter and full-year results reflect the strong execution of our 3x3 Plan, accelerating our client-centric Aon United strategy"INDEXES:Near midday, the Dow was down 0.84%, or 414.43, to 48,657.13, the Nasdaq was down 0.64%, or 151.85, to 23,533.28, and the S&P 500 was down 0.51%, or 35.80, to 6,933.21.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.